Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: A randomized phase II clinical trial

Journal of Thoracic Oncology

Volumn 4, Issue 9, 2009, Pages 1148-1155

  Zwitter, Matjaz ^a,b   Kovac, Viljem ^a   Smrdel, Uros ^a   Vrankar, Martina ^a   Zadnik, Vesna ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY OF MARIBOR   (Slovenia)

Author keywords

Cisplatin; Gemcitabine; Non small cell lung cancer; Prolonged infusion; Randomized clinical trial

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL RESEARCH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG INFUSION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; ONCOLOGY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOCYTOSIS; WEIGHT REDUCTION; WELLBEING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 69549116226     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ae280f     Document Type: Article

References (28)

1. Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997;15:310-316.
2. Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 1998;9:1003-1008. (Pubitemid 28496710)
3. Ceribelli A, Gridelli C, De Marinis F, et al. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 2003;98:337-343. (Pubitemid 36828459)
4. Cappuzzo F, Novello S, De Marinis F, et al. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-smallcell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 2006;52:319-325. (Pubitemid 44275321)
5. Gridelli C, De Maio E, Barbera S, et al. The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients. Lung Cancer 2008;61:67-72. (Pubitemid 351862324)
6. Anderson H, Thatcher N, Walling J, Hansen H. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 1996;74:460-462. (Pubitemid 26254579)
7. Akrivakis K, Schmid P, Flath B, et al. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 1999;10:525-531. (Pubitemid 29410798)
8. Maurel J, Zorrilla M, Puertolas T, et al. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 2001;12:713-717. (Pubitemid 33001183)
9. 2) levels. Invest New Drugs 1997;15:115-121.
10. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991;27:258-262.
11. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-499.
12. Cattel L, Airoldi M, Delprino L, Passera R, Milla P, Pedani F. Pharmacokinetic evaluation of gemcitabine and 2′,2′- difluorodeoxycytidine-5′-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol 2006;17(Suppl 5):v142-v147. (Pubitemid 43985224)
13. Schmid P, Heilmann V, Schulz CO, et al. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. J Cancer Res Clin Oncol 2005;131:568-574. (Pubitemid 41558548)
14. Schmid P, Krocker J, Jehn C, et al. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Ann Oncol 2005;16:1624-1631. (Pubitemid 41510136)
15. Eckel F, Schmelz R, Erdmann J, Mayr M, Lersch C. Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest 2003;21:690-694. (Pubitemid 37377323)
16. Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000;11:325-329. (Pubitemid 30459467)
17. Sezer O, Eucker J, Jakob C, Kaufmann O, Schmid P, Possinger K. Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine. Invest New Drugs 2001;19:101-104. (Pubitemid 32209792)
18. Khaled H, Emara ME, Gaafar RM, et al. Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a phase II trial. Urol Oncol 2008;26:133-136. (Pubitemid 351288557)
19. von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid RM, Eckel F. Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 2005;5:61. (Pubitemid 41471954)
20. Schmid P, Schweigert M, Beinert T, Flath B, Sezer O, Possinger K. Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study. Invest New Drugs 2005;23:139-146. (Pubitemid 40386231)
21. Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B, Vrankar M. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 2005;16:1129-1134. (Pubitemid 41565779)
22. Xiong JP, Feng M, Qiu F, et al. Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Lung Cancer 2008;60:208-214. (Pubitemid 351609148)
23. Parikh PM, Narayanan P, Mistry RC, et al. Treatment of advanced NSCLC (stage IIIB and IV) with low dose gemcitabine and carboplatin. J Clin Oncol 2005;23:7306.
24. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer 2009;45:275-280.
25. Dalton SO, Steding-Jessen M, Engholm G, Schüz J, Olsen JH. Social inequality and incidence of and survival from lung cancer in a population-based study in Denmark, 1994-2003. Eur J Cancer 2008;44:1989-1995.
26. Menon H, Vora A, Chaudhry K, Behera Z. Lung cancer - global versus Indian scenario. In: Hingmire S, Prabash K, (Eds.), Lung Cancer, Vol 2. Mumbai, India: The Oncology Knowledge Bank, Green Room Media, 2008. Pp. 318-331.
27. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
28. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.